Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Controlled Study to Evaluate the Efficacy and Safety of Endocrine Therapy Plus Chemotherapy Versus Chemotherapy Alone as the Neoadjuvant Therapy in the Treatment of ER-positive, HER2-negative Breast Cancer (IIa-IIIc)

NCT02980965 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT02980965
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02980965 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Controlled Study to Evaluate the Efficacy and Safety of Endocrine Therapy Plus Chemotherapy Versus Chemotherapy Alone as the Neoadjuvant Therapy in the Treatment of ER-positive, HER2-negative Breast Cancer (IIa-IIIc)
Lead sponsor
Fudan University
Phase
Phase 3
Overall status
Completed
Start date
May 31, 2013
Completion date
February 28, 2017
Enrollment
249 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer female